Back

Find the FamiCord brand in your country

Free guide

Smart Cells free guide

Download

Transplant stories

Real Treatments. Real Families. Real Hope.

Smart Cells was the first private UK stem cell bank to release samples for transplant — proving that family cord blood banking is not just about storage, but about delivering real therapies when they are needed most.

Why Stem Cell Transplants Matter

At some point in life, your child or family member may need access to stem cell therapy. Today, these treatments are being used for:

  • Blood cancers such as leukaemia and lymphoma
  • Inherited genetic disorders including thalassemia and sickle cell disease
  • Neurological conditions such as cerebral palsy and brain injury
  • Immune deficiencies and metabolic disorders
  • Emerging therapies for sports injuries, inflammatory conditions, and skin repair

By preserving your baby’s umbilical cord blood and tissue, you safeguard access to these life-saving and life-enhancing possibilities.

Proven Track Record

Smart Cells has released more stem cell samples for treatment than any other private UK bank, with a 100% success rate for every sample delivered to clinicians worldwide.

These samples have helped children and families across the globe face illnesses such as:

  • Cerebral Palsy
  • Thalassemia
  • Leukaemia
  • HSV Encephalitis
  • Immune system disorders

Each transplant is more than a statistic — it represents a child given new options, and a family given hope.

A Milestone for Families and for Science

Every successful release shows how far the field of stem cell research has advanced. What was once only a possibility is now a proven therapy.

Yet many parents are still unaware of the benefits of storing their baby’s cord blood and tissue. Smart Cells is working to change that — by raising awareness, sharing real transplant stories, and supporting research into the next generation of regenerative treatments.

Powered by FamiCord: Europe’s Stem Cell Leader in banking and use of cells

As part of the FamiCord Group, Europe’s largest family stem cell bank and one of the world’s top three:

  • Families gain access to 1,000,000+ stored cord blood units across the network
  • Therapies are supported by specialist research centres and clinical teams in 35+ countries including FamiCord Programme for brain disorders
  • FamiCordTx, the group’s advanced therapies division, is actively developing new cell-based treatments to extend the possibilities for families everywhere

Together, Smart Cells and FamiCord stand at the forefront of innovation, offering parents confidence today — and hope for tomorrow.

FamiCord Group releases

Patients

7800+

Expand table
No. Source Source type Diagnosis Medical sector Year of application Therapy Country Age of the recipient
901 Bone Marrow Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 5
902 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 58
903 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 34
904 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 61
905 Apheresis Allogeneic Myelodysplastic Syndrome/Myeloproliferative neoplasm Hematology 2025 Standard Therapy NETHERLANDS 62
906 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Austria 68
907 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 70
908 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
909 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 77
910 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Ukraine 12
911 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 58
912 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 67
913 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 4
914 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 73
915 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 56
916 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Italy 50
917 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 39
918 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Lithuania 43
919 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy Poland 66
920 Apheresis Allogeneic Multiple Myeloma Hematology 2025 Standard Therapy USA 61
921 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Austria 55
922 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 69
923 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Denmark 67
924 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy United Kingdom 75
925 Apheresis Allogeneic T – cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 24
926 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Belgium 68
927 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Ukraine 42
928 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy USA 50
929 Apheresis Allogeneic Prolymphocytic Leukemia Hematology 2025 Standard Therapy USA 62
930 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy United Kingdom 62
931 Apheresis Allogeneic Chronic Myelomonocytic Leukemia Hematology 2025 Standard Therapy USA 69
932 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 85
933 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 54
934 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy USA 39
935 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 45
936 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 59
937 Apheresis Allogeneic Multiple myeloma Hematology 2025 Standard Therapy Germany 68
938 Apheresis Allogeneic Multiple myeloma Hematology 2025 Standard Therapy Germany 68
939 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 73
940 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 66
941 Apheresis Autologous Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 69
942 Apheresis Autologous Hodgkin lymphoma Hematology 2025 Standard Therapy Germany 38
943 Apheresis Allogeneic Tcell acute leukemia Hematology 2025 Standard Therapy Romania 31
944 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Italy 37
945 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Sweden 69
946 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 55
947 Apheresis Allogeneic Fanconi's Anemia Hematology 2025 Standard Therapy Russia 14
948 Apheresis Allogeneic Peripheral T-cell Lymphoma not otherwise specified Hematology 2025 Standard Therapy Germany 54
949 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy France 63
950 Apheresis Allogeneic Myeloid Sarcoma Hematology 2025 Standard Therapy Poland 48
951 Apheresis Allogeneic Other Myelofibrosis/Myelosclerosis Hematology 2025 Standard Therapy USA 72
952 Apheresis Allogeneic Severe Aplastic Anemia Hematology 2025 Standard Therapy Germany 11
953 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 37
954 Apheresis Allogeneic Myelofibrosis Hematology 2025 Standard Therapy Australia 59
955 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 35
956 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 51
957 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 59
958 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 70
959 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy USA 70
960 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 66
961 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 63
962 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 66
963 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Italy 61
964 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy USA 71
965 Apheresis Allogeneic Chronic Lymphocytic Leukemia Hematology 2025 Standard Therapy Czechia 45
966 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Brazil 61
967 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Hungary 35
968 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy NETHERLANDS 48
969 Apheresis Allogeneic Mantle Cell Lymphoma Hematology 2025 Standard Therapy Ireland 62
970 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 62
971 Apheresis Allogeneic Acute Myeloid Leukemia, Myelodysplasia-Related Hematology 2025 Standard Therapy Russia 53
972 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 56
973 Apheresis Allogeneic Myelofibrosis Myeloid Metaplasia Hematology 2025 Standard Therapy USA 68
974 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 70
975 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Germany 62
976 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 53
977 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 52
978 Apheresis Autologous Diffuse large B-cell lymphoma Hematology 2025 Standard Therapy Germany 63
979 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 72
980 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 64
981 Apheresis Allogeneic Acute myeloid leukemia Hematology 2025 Standard Therapy Germany 74
982 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Germany 65
983 Apheresis Allogeneic T-cell prolymphocytic leukemia Hematology 2025 Standard Therapy Germany 53
984 Apheresis Autologous Central nervous system lymphoma Hematology 2025 Standard Therapy Germany 70
985 Apheresis Autologous Multiple myeloma Hematology 2025 Standard Therapy Germany 61
986 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 54
987 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 41
988 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 32
989 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 72
990 Apheresis Allogeneic Non-Hodgkin Lymphoma Hematology 2025 Standard Therapy Poland 52
991 Apheresis Allogeneic Chronic Myeloid Leukemia Hematology 2025 Standard Therapy Poland 50
992 Apheresis Allogeneic T-cell Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 17
993 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 66
994 Apheresis Allogeneic Multiple Myeloma Hematology 2025 Standard Therapy Poland 49
995 Apheresis Allogeneic Chronic Granulomatous Disease Hematology 2025 Standard Therapy Poland 5
996 Apheresis Allogeneic Myelodysplastic Syndrome Hematology 2025 Standard Therapy Poland 55
997 Apheresis Allogeneic Diffuse Large B-cell Lymphoma Hematology 2025 Standard Therapy Poland 68
998 Apheresis Allogeneic Acute Lymphoblastic Leukemia Hematology 2025 Standard Therapy Poland 64
999 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 51
1000 Apheresis Allogeneic Acute Myelogenous Leukemia Hematology 2025 Standard Therapy Poland 58
Expand table

Stem cell transplantation has become an established procedure

700,000

cord blood collections have been undertaken globally

50,000

hematopoietic stem cell transplants take place every year

400/500

of these transplants are in Europe

Our transplant stories

Smart Cells have released 24 UK
samples to six countries.

Stem cells hold the key to more than 80 life-changing treatments, with clinical trials underway on many more. Replacing damaged cells and tissue, they can even save a child’s life.

Icon

100% infusion success rate

For samples released for transplant.

Icon

3 months – 12 yrs old

Stored cord blood samples have been successfully released for use in transplant for children aged as little as 3 months to 12 years old.

Icon

46% self | 54% siblings

Smart Cells have successfully released stored cord blood samples that have been used for treatment with the child it was collected from and also siblings.

Smart Cells releases

UK samples released

24

Expand table
Sample release date Medical condition Recipient relationship Age of the recipient Unit volume Medical center Country
2005.11 Thalassemia Allogeneic (Sibling) 4 Years 144ml Mount Vernon Hospital Singapore
2005.11 Leukaemia Allogeneic (Sibling) Restricted Restricted Stem Cells and Immunology Department, Birmingham UK
2007.02 Thalassemia Allogeneic (Sibling) 7 Years 76ml Kinderlink der Tu Munchen Germany
2009.08 Cerebral Palsy Autologous (Self) 3 Years 51ml Duke University, North Carolina USA
2010.01 Cerebral Palsy Autologous (Self) 3 Years 81ml Duke University, North Carolina USA
2013.10 Thalassemia Allogeneic (Sibling) 5 Years 58ml Catherine Lewis Centre, Hammersmith UK
2014.01 Leukaemia Allogeneic (Sibling) 4 Years 71ml Medizinische Hochschule, Hanover Germany
2014.05 Cerebral Palsy Autologous (Self) 1 year 68ml Duke University, North Carolina USA
2014.06 HSV Encephalitis & NMDA Receptor Antibody Virus Autologous (Self) 2 Years 57ml Duke University, North Carolina USA
2014.08 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 3 Months 39ml Duke University, North Carolina USA
2015.02 Hypoxic Ischemic Encephalopathy (HIE) Autologous (Self) 6 Months 53ml Duke University, North Carolina USA
2015.03 Severe Combined Immune Deficiency Autologous (Self) 3 Months 74ml Duke University, North Carolina USA
2015.03 Sickle Cell Disease Allogeneic (Sibling) 2 .5 Years 57ml BLK Hospital, New Delhi India
2015.11 Thalassemia Allogeneic (Sibling) 12 Years 87ml Children’s Hospital of Pittsburgh of UPMC USA
2016.03 Cerebral Palsy Allogeneic (Sibling) 6 Years 101ml Duke University, North Carolina USA
2017.04 Lymphoblastic Leukaemia (^1) N/A (Identical twin girls) Restricted 125ml Bambin Gesu Childrens’ Hospital, Rome Italy
2017.06 Cerebral Palsy Autologous (Self) 7 Years 82ml Duke University, North Carolina USA
2017.06 Cerebral Palsy Autologous (Self) 3.4 Years 132ml Duke University, North Carolina USA
2018.03 Autism Autologous (Self) 5.4 Years 73ml Duke University, North Carolina USA
2018.03 Cerebral Palsy Autologous (Self) 3.4 years 132ml Duke University, North Carolina USA
2019.06 Cerebral Palsy Allogeneic (Sibling) 3 Years 104ml Duke University, North Carolina USA
2022.02 Cerebral Palsy Allogeneic (Sibling) 11 Years 185ml Duke University, North Carolina USA
2023.08 Cerebral Palsy Allogeneic (Sibling) 3 Years 46ml Duke University, North Carolina USA
2024.01 Thalassaemia Allogeneic (Sibling) 8 Years 45ml Cincinnati Children’s Hospital Medical Center USA
Expand table
Icon

Ready to get started or need more information?